CJC-1295 (No DAC) and Ipamorelin are two peptides commonly studied together for their complementary effects on growth hormone secretion. CJC-1295 (No DAC) is a growth hormone–releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue. When combined, research has explored their ability to stimulate pulsatile GH release while minimizing unwanted activity on other hormone pathways. This blend has become a foundational research tool for studying body composition, recovery, sleep-related hormone cycles, and metabolic vitality.
 
Research Outcomes in Studies:
Studies show increased growth hormone and IGF-1 levels through synergistic GHRH and GHS activity.
Research suggests improved body composition, with fat reduction and lean tissue preservation in certain models.
Investigated for enhanced recovery and tissue repair pathways linked to GH signaling.
Studies report minimal impact on cortisol and prolactin compared to less selective secretagogues.
Explored for potential sleep quality and circadian hormone rhythm effects.
 
Reference Guide
For deeper research frameworks and pathway explanations, visit The Forge Research Guide.
 
For laboratory research use only. Not for human or veterinary consumption. Not FDA evaluated.